NCT02951533View on ClinicalTrials.gov

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL

Enrollment

119

Participants

Timeline

Start Date

December 12, 2016

Primary Completion Date

September 13, 2017

Study Completion Date

February 6, 2019

Conditions

Psoriasis

Interventions

DRUG

Guselkumab

Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.

DRUG

Fumaric Acid Esters

Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.

Trial Locations (28)

Unknown

Augsburg

Berlin

Bielefeld

Dresden

Dülmen

Düsseldorf

Erlangen

Essen

Frankfurt

Gera

Hamburg

Heidelberg

Jena

Kiel

Leipzig

Lübeck

Mahlow

Mainz

Memmingen

München

Münster

Neu-Ulm

Osnabrück

Selters

Stuttgart

Tübingen

Witten

Wuppertal

All Listed Sponsors

lead

Janssen-Cilag G.m.b.H

INDUSTRY

NCT02951533 - A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter